Terms: = Endocrine gland cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C
66 results:
1. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
2. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling the role of KRAS in tumor immune microenvironment.
Xu M; Zhao X; Wen T; Qu X
Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
[TBL] [Abstract] [Full Text] [Related]
4. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based shp2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
5. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract] [Full Text] [Related]
6. Major Venous Repair or Reconstruction During Laparoscopic Pancreatic Surgery: A Single Center's Experience.
Jie Z; Zhou X; Haibiao W; Ying D; Chen B; Li H
J Laparoendosc Adv Surg Tech A; 2023 Sep; 33(9):890-896. PubMed ID: 37074117
[No Abstract] [Full Text] [Related]
7. Disruption of Ovarian cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase.
Lazo JS; Isbell KN; Vasa SA; Llaneza DC; Rastelli EJ; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2023 Mar; 384(3):429-438. PubMed ID: 36627205
[TBL] [Abstract] [Full Text] [Related]
8. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
9. Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation.
Li GN; Zhao XJ; Wang Z; Luo MS; Shi SN; Yan DM; Li HY; Liu JH; Yang Y; Tan JH; Zhang ZY; Chen RQ; Lai HL; Huang XY; Zhou JF; Ma D; Fang Y; Gao QL
Signal Transduct Target Ther; 2022 Sep; 7(1):317. PubMed ID: 36097006
[TBL] [Abstract] [Full Text] [Related]
10. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Khan I; Marelia-Bennet C; Lefler J; Zuberi M; Denbaum E; Koide A; Connor DM; Broome AM; Pécot T; Timmers C; Ostrowski MC; Koide S; O'Bryan JP
Small GTPases; 2022 Jan; 13(1):114-127. PubMed ID: 33949915
[No Abstract] [Full Text] [Related]
11. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.
Gualtieri A; Kyprianou N; Gregory LC; Vignola ML; Nicholson JG; Tan R; Inoue SI; Scagliotti V; Casado P; Blackburn J; Abollo-Jimenez F; Marinelli E; Besser REJ; Högler W; Karen Temple I; Davies JH; Gagunashvili A; Robinson ICAF; Camper SA; Davis SW; Cutillas PR; Gevers EF; Aoki Y; Dattani MT; Gaston-Massuet C
Nat Commun; 2021 Apr; 12(1):2028. PubMed ID: 33795686
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing cancer Cell Growth.
Ishii H; Zahra MH; Takayanagi A; Seno M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
[TBL] [Abstract] [Full Text] [Related]
13. PD-1 blockade delays tumor growth by inhibiting an intrinsic shp2/Ras/MAPK signalling in thyroid cancer cells.
Liotti F; Kumar N; Prevete N; Marotta M; Sorriento D; Ieranò C; Ronchi A; Marino FZ; Moretti S; Colella R; Puxeddu E; Paladino S; Kano Y; Ohh M; Scala S; Melillo RM
J Exp Clin Cancer Res; 2021 Jan; 40(1):22. PubMed ID: 33413561
[TBL] [Abstract] [Full Text] [Related]
14. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract] [Full Text] [Related]
15. ptpn11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
[TBL] [Abstract] [Full Text] [Related]
16. Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis.
Tacelli M; Celsa C; Magro B; Barchiesi M; Barresi L; Capurso G; Arcidiacono PG; Cammà C; Crinò SF
Dig Endosc; 2020 Nov; 32(7):1018-1030. PubMed ID: 31912580
[TBL] [Abstract] [Full Text] [Related]
17. Thyroid cancer MR molecular imaging via shp2-targeted nanoparticles.
Hu Z; Qin J; Li T; Guo J
Int J Nanomedicine; 2019; 14():7365-7373. PubMed ID: 31686812
[TBL] [Abstract] [Full Text] [Related]
18. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological and prognostic significance of shp2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract] [Full Text] [Related]
20. Mutant KRAS-driven cancers depend on ptpn11/shp2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract] [Full Text] [Related]
[Next]
